Literature DB >> 34181149

68Ga-FAPI-04 PET/MR is helpful in differential diagnosis of pancreatitis from pancreatic malignancy compared to 18F-FDG PET/CT: a case report.

Yi Shou1, Qiaoyi Xue2, Jianmin Yuan2, Jun Zhao3.   

Abstract

INTRODUCTION: 68Ga-fibroblast activation protein-specific enzyme inhibitor 04 (FAPI-04) is a radiolabelled molecular agent targeting the inhibitor of fibroblast activation protein (FAP), which is often present in tumor stroma and inflammatory tissue with prominent fibroblast proliferation. FAPI-04 is a promising PET tracer for tumor imaging as well as IgG4-related disease (IgG4-RD). CASE DESCRIPTION: We herein present a case where 68Ga-FAPI PET/MR helped to diagnose IgG4-RD that involved pancreas and bile duct. A 62-year-old patient suffered from diffusive discomfort at middle upper abdomen and presented brown urine. Blood test revealed abnormal liver function and elevated IgG4 (4.830g/L↑). 18F-FDG PET showed enlarged uncinate process and dilated bile duct tree. Mild increase of FDG uptake in uncinate process and head of pancreas indicated possible pancreatic malignancy, but the clinical evidence was not sufficient and histology examination was negative. 68Ga-FAPI PET revealed prominent increased radioactivity distribution in the entire pancreas and bile duct, suggesting IgG4-RD.
CONCLUSION: FAPI-04 is not only a good PET imaging tracer for tumors, but also for prominent fibroblast-mediated inflammation. FAPI imaging should be considered when the diagnosis using 18F-FDG imaging is ambiguous. The presented case illustrates that 68Ga-FAPI-04 PET is helpful in improving the differential diagnosis of pancreatitis and pancreatic cancer.

Entities:  

Keywords:  68Ga-FAPI; IgG4-RD; PET/CT; PET/MR; Pancreatic cancer; Pancreatitis

Year:  2021        PMID: 34181149     DOI: 10.1186/s41824-021-00106-1

Source DB:  PubMed          Journal:  Eur J Hybrid Imaging        ISSN: 2510-3636


  9 in total

Review 1.  ¹⁸F-FDG PET/CT imaging of the pancreas: spectrum of diseases.

Authors:  Vien X Nguyen; Cuong C Nguyen; Ba D Nguyen
Journal:  JOP       Date:  2011-11-09

2.  Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein.

Authors:  Thomas Lindner; Anastasia Loktev; Annette Altmann; Frederik Giesel; Clemens Kratochwil; Jürgen Debus; Dirk Jäger; Walter Mier; Uwe Haberkorn
Journal:  J Nucl Med       Date:  2018-04-06       Impact factor: 10.057

3.  Focal Autoimmune Pancreatitis Mimicking Pancreatic Cancer on FDG PET/CT Imaging.

Authors:  Lichun Zheng; Haiqun Xing; Fang Li; Li Huo
Journal:  Clin Nucl Med       Date:  2018-01       Impact factor: 7.794

4.  IgG4-related disease revealed by 68Ga-FAPI and 18F-FDG PET/CT.

Authors:  Yaping Luo; Qingqing Pan; Wen Zhang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-08-13       Impact factor: 9.236

5.  Fibroblast Activation Protein-Targeted PET/CT with 68Ga-FAPI for Imaging IgG4-Related Disease: Comparison to 18F-FDG PET/CT.

Authors:  Yaping Luo; Qingqing Pan; Huaxia Yang; Linyi Peng; Wen Zhang; Fang Li
Journal:  J Nucl Med       Date:  2020-06-08       Impact factor: 10.057

6.  Recurrent Immunoglobulin G4-Related Disease Shown on 18F-FDG and 68Ga-FAPI PET/CT.

Authors:  Qingqing Pan; Yaping Luo; Wen Zhang
Journal:  Clin Nucl Med       Date:  2020-04       Impact factor: 7.794

7.  Intense FAPI Uptake in Inflammation May Mask the Tumor Activity of Pancreatic Cancer in 68Ga-FAPI PET/CT.

Authors:  Yaping Luo; Qingqing Pan; Wen Zhang; Fang Li
Journal:  Clin Nucl Med       Date:  2020-04       Impact factor: 7.794

8.  Characterizing IgG4-related disease with ¹⁸F-FDG PET/CT: a prospective cohort study.

Authors:  Jingjing Zhang; Hua Chen; Yanru Ma; Yu Xiao; Na Niu; Wei Lin; Xinwei Wang; Zhiyong Liang; Fengchun Zhang; Fang Li; Wen Zhang; Zhaohui Zhu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-04-25       Impact factor: 9.236

9.  A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts.

Authors:  Anastasia Loktev; Thomas Lindner; Walter Mier; Jürgen Debus; Annette Altmann; Dirk Jäger; Frederik Giesel; Clemens Kratochwil; Philippe Barthe; Christian Roumestand; Uwe Haberkorn
Journal:  J Nucl Med       Date:  2018-04-06       Impact factor: 10.057

  9 in total
  2 in total

Review 1.  Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond.

Authors:  Mengting Li; Muhsin H Younis; Yongxue Zhang; Weibo Cai; Xiaoli Lan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-01-31       Impact factor: 10.057

Review 2.  FAPI PET/CT in the Diagnosis of Abdominal and Pelvic Tumors.

Authors:  Tianshuo Yang; Long Ma; Haodong Hou; Feng Gao; Weijing Tao
Journal:  Front Oncol       Date:  2022-01-04       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.